CorMedix has a Beta of 0.58, indicating that it may offer some diversification benefits in a portfolio. This means that when the market rises, CorMedix is likely to rise less, but it should also experience smaller losses during downturns. Currently, the stock has a negative expected return of -0.49%. It’s important to check CorMedix’s kurtosis and the relationship between its maximum drawdown and rate of daily change. These factors can help you determine whether CorMedix's past performance is likely to repeat in the near future. Always do your due diligence before making any investment decisions.
Primary Takeaways
CorMedix Inc. is generating buzz, but investors should tread carefully. With a current price of
3.78, the stock has shown a troubling Jensen Alpha of -0.65, indicating underperformance compared to the market. As the company focuses on its lead product, DefenCath, the potential upside of
3.49 may not be enough to offset the risks, especially given the recent loss in market risk adjusted performance of -1.1. With these factors in play, it might be wise to consider shorting CorMedix as the hype may not translate into sustainable growth.
The successful prediction of CorMedix
stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published
stock prices of traded companies, such as CorMedix, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at
the intrinsic value of CorMedix based on CorMedix hews, social hype, general headline patterns, and widely used
predictive technical indicators. We also calculate exposure to CorMedix's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to CorMedix's related companies.
Use Technical Analysis to project CorMedix expected Price
CorMedix technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of CorMedix technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of CorMedix trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions.
More Info...CorMedix Gross Profit
CorMedix Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing CorMedix previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show CorMedix Gross Profit growth over the last 10 years. Please check CorMedix's
gross profit and other
fundamental indicators for more details.
Breaking it down
Net Loss for the year was (46.34
M) with profit before overhead, payroll, taxes, and interest of 61.67
K.
| 2023 | 2024 (projected) |
Dividend Yield | 0.0202 | 0.0179 | Price To Sales Ratio | 3.0K | 1.6K |
Current Deferred Revenue Breakdown
CorMedix's Current Deferred Revenue is decreasing over the years with stable fluctuation. Current Deferred Revenue is expected to dwindle to 1,886. Current Deferred Revenue usually refers to revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. At present, CorMedix's Current Deferred Revenue is projected to decrease significantly based on the last few years of reporting.
| 2010 | 8,823 |
| 2015 | 130,409 |
| 2016 | 104,210 |
| 2017 | 88,404 |
| 2018 | 11,029 |
| 2019 | 2,206 |
| 2023 | 1,985.4 |
| 2024 | 1,886.13 |
In investing, what goes up must come down, and CorMedix Inc. may be facing a downturn. With a staggering probability of bankruptcy at 49.40% and a return on equity of -0.90, the company’s financial health raises red flags for potential investors. Despite a market capitalization of $209.94 million and a target price of $12.50, the current price-to-book ratio of 3.45 suggests that the stock may be overvalued. Additionally, the high short ratio of 21.17 indicates that many investors are betting against the stock, further signaling a lack of confidence in its future performance. Given these factors, it may be prudent to consider shorting CorMedix as a strategic investment move.
Our take on today CorMedix surge
CorMedix has seen a significant rise today, even as its risk level has dropped to -4.71. This decrease in risk suggests some market fluctuations, but the stock's recent gains may reflect increasing investor confidence. As the market responds to the company's latest news, it will be intriguing to see if this positive trend continues, potentially creating an attractive opportunity for investors interested in a company with strong potential.
CorMedix shows low volatility, with a skewness of 0.92 and kurtosis of 2.37. Understanding market volatility can help investors time their moves. High volatility during bear markets can affect CorMedix's stock price, causing stress for investors as they watch their shares decline.
This often leads to portfolio adjustments as they seek to buy different assets at lower prices.As we look ahead to September, CorMedix presents an intriguing investment opportunity, particularly for those interested in the biopharmaceutical sector. With a strong buy consensus among analysts and a possible upside price of
5.97, the stock could be poised for significant movement. The company’s focus on innovative solutions like DefenCath, aimed at reducing serious infections in vulnerable patients, highlights its potential for growth. While the naive expected forecast value sits at
3.17, the market is buzzing with optimism, as evidenced by the analyst target price estimated at
12.33. Investors should keep a close eye on developments this September, as any positive news could propel the stock even higher..
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Gabriel Shpitalnik is a Member of Macroaxis Editorial Board. Gabriel is a young entrepreneur and writes predominantly on the business, technology, and finance sector. He likes to analyze different equity instruments across a wide range of industries focusing primarily on consumer products and evolving technologies.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of CorMedix. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]
